ResearcherUniversity of GlasgowActive in the last 2 years

Katharine J. Herbert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9437-0253; OpenAlex author ID A5052857819. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03051-z ↗
Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC. Co-author DOI 10.1038/s41598-024-59451-3 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

David Kuang-Fu Chang · 2 shared papers, 2024–2025 · strength 0.42
- Paper Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-025-03051-z ↗
- Paper Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF depende… DOI 10.1038/s41598-024-59451-3 ↗
Andrew Victor Biankin · 2 shared papers, 2024–2025 · strength 0.42
- Paper Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-025-03051-z ↗
- Paper Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF depende… DOI 10.1038/s41598-024-59451-3 ↗
Australian Pancreatic Cancer Genome Initiative · 1 shared paper, 2025 · strength 0.23
- Paper Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-025-03051-z ↗
Stephan B. Dreyer · 1 shared paper, 2025 · strength 0.23
- Paper Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-025-03051-z ↗
Fieke E. M. Froeling · 1 shared paper, 2025 · strength 0.23
- Paper Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-025-03051-z ↗
Christian P. Pilarsky · 1 shared paper, 2025 · strength 0.23
- Paper Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-025-03051-z ↗
Sean F Cooke · 1 shared paper, 2024 · strength 0.19
- Paper Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF depende… DOI 10.1038/s41598-024-59451-3 ↗
Connor M. Blair · 1 shared paper, 2024 · strength 0.19
- Paper Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF depende… DOI 10.1038/s41598-024-59451-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.